Sign in
4

Changes in Ownership

Cullinan Therapeutics, Inc. Filed Acc 0000950170-24-007032

Chief Business Officer sold 40,000 shares at an average $12.31 ($492,508)

  • Chief Business Officer acquired 35,875 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Savill Corrine Chief Business Officer 2024-01-22 Option exercise 10b5-1 +14,559 $4.30 $62,604 184,674 D: show line 1 in the form
Savill Corrine Chief Business Officer 2024-01-22 Sale 10b5-1 −14,559 $12.18 $177,329 170,115 D: show line 2 in the form
Savill Corrine Chief Business Officer 2024-01-22 Sale 10b5-1 −4,125 $12.02 $49,583 165,990 D: show line 3 in the form
Savill Corrine Chief Business Officer 2024-01-23 Option exercise 10b5-1 +21,316 $4.30 $91,659 187,306 D: show line 4 in the form
Savill Corrine Chief Business Officer 2024-01-23 Sale 10b5-1 −21,316 $12.46 $265,597 165,990 D: show line 5 in the form
Open-market sales · 40,000 sh · avg $12.31 · $492,508

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Savill Corrine Chief Business Officer 2024-01-22 Option exercise · Stock Option (Right to Buy) 10b5-1 −14,559 35,313 D: show line 6 in the form
Savill Corrine Chief Business Officer 2024-01-23 Option exercise · Stock Option (Right to Buy) 10b5-1 −21,316 13,997 D: show line 7 in the form
Loading xslF345X05/ownership.xml…